Recce Pharmaceuticals (ASX:RCE) to dual list on FSE

Recce Pharmaceuticals (ASX:RCE) to dual list on FSE

• Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE) • The company has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe • DGWA will engage prospective investors and drive awareness of Recce's products • Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union • The company will keep the market updated as the listing progresses • Shares in Recce are steady on the market and are trading at $1.05 per share Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE). The FSE is the tenth-largest stock exchange in the world, third-largest in Europe and is owned and operated by Deutsche Börse AG and Börse Frankfurt Zertifikate AG. Recce has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe. DGWA will engage prospective investors and drive awareness of Recce's products. "We are excited to support Recce in engagement with European investors and opportunities …
More on: themarketherald.com.au